The9’s Investee Nanyang Biologics (NYB) Advancing toward Nasdaq Listing after RFAI Cleared Vote at Shareholders Extraordinary General Meeting

Milestone Marks Further Progress in The9’s Strategic Investment in AI-Driven Drug Discovery; The9 Expects to Hold Approximately 15% to 16% of the Combined, Nasdaq-Listed Company SHANGHAI, Aug. 21, 2026 /PRNewswire/ — The9 Limited (Nasdaq: NCTY) (“The9” or the “Company”), a global, diversified high-tech company, today announced that Nanyang Biologics Pte. Ltd. (“NYB”), a Singapore-based, AI-driven drug [...]